NEW DEVELOPMENT AGAINST THE PANDEMIC
NEOKIT PLUS, a new rapid diagnostic test of COVID-19, was approved by the ANMAT
It reduces diagnostic time and cost as it detects the virus from swab or saliva.
The ‘National Administration of Drugs, Food and Medical Devices’ (ANMAT) approved NEOKIT PLUS, a new rapid diagnostic test of simplified molecular detection of the SARS-CoV-2 virus. From a direct clinical sample obtained by swabbing or saliva, the new technological device will reduce significant time and costs in diagnosis.
NEOKIT PLUS improves the original version of NEOKIT COVID-19 because it extracts the viral genome without previous purification of the virus RNA.
This is another new Argentine development to fight the pandemic that shows the potential and quality of the local scientific and technological system.
About NEOKIT COVID-19 and NEOKIT PLUS
NEOKIT COVID-19 and NEOKIT PLUS have been developed by CONICET scientists at the Instituto Dr. César Milstein, as part of the ‘Unit Coronavirus COVID-19’ created by the ‘Ministry of Science, Technology and Innovation, CONICET and the ‘Agency I+D+i.
Both tests are highly reliable, easy to use, economical and provide a rapid diagnostic.
The tests have been produced in the country after the agreement between NEOKIT and Y-TEC, the technological company of YPF and CONICET.